|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
47,500,000 |
Market
Cap: |
2.00(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$38.65 - $65 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Amphastar Pharmaceuticals is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient (API) products. Co.'s reportable segments are: finished pharmaceutical products, which manufactures, markets and distributes Primatene Mist®, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs; and API, which manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
32,136 |
392,652 |
607,225 |
795,101 |
Total Sell Value |
$1,498,005 |
$22,016,859 |
$33,327,809 |
$40,665,283 |
Total People Sold |
3 |
5 |
9 |
10 |
Total Sell Transactions |
5 |
13 |
27 |
63 |
End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Gerst Diane G. |
EVP, QA & Regulatory Affairs |
|
2017-10-05 |
4 |
OE |
$11.33 |
$95,671 |
D/D |
8,444 |
42,792 |
|
- |
|
Petersen Floyd F. |
Director |
|
2017-10-04 |
4 |
AS |
$18.59 |
$730,755 |
D/D |
(39,312) |
64,561 |
|
- |
|
Petersen Floyd F. |
Director |
|
2017-10-04 |
4 |
OE |
$10.77 |
$423,390 |
D/D |
39,312 |
103,873 |
|
- |
|
Zasloff Michael A |
Director |
|
2017-10-02 |
4 |
AS |
$18.18 |
$1,156,952 |
D/D |
(63,624) |
38,255 |
|
- |
|
Zasloff Michael A |
Director |
|
2017-10-02 |
4 |
OE |
$10.77 |
$685,230 |
D/D |
63,624 |
101,879 |
|
- |
|
Luo Mary Z. |
COO,Chief Scientist & Chairman |
|
2017-09-13 |
4 |
D |
$15.87 |
$1,912,398 |
I/I |
(120,504) |
1,076,833 |
|
- |
|
Luo Mary Z. |
COO,Chief Scientist & Chairman |
|
2017-09-13 |
4 |
OE |
$11.53 |
$1,598,427 |
I/I |
138,632 |
1,197,337 |
|
- |
|
Luo Mary Z. |
COO,Chief Scientist & Chairman |
|
2017-09-13 |
4 |
D |
$15.86 |
$2,440,569 |
D/D |
(153,882) |
1,578,055 |
|
- |
|
Luo Mary Z. |
COO,Chief Scientist & Chairman |
|
2017-09-13 |
4 |
OE |
$11.53 |
$2,040,660 |
D/D |
176,987 |
1,731,937 |
|
- |
|
Prins Richard K |
Director |
|
2017-08-15 |
4 |
S |
$14.82 |
$74,087 |
D/D |
(5,000) |
28,844 |
|
- |
|
Prins Richard K |
Director |
|
2017-08-15 |
4 |
OE |
$10.77 |
$53,850 |
D/D |
5,000 |
33,844 |
|
- |
|
Prins Richard K |
Director |
|
2017-08-14 |
4 |
S |
$14.80 |
$73,997 |
D/D |
(5,000) |
28,844 |
|
- |
|
Prins Richard K |
Director |
|
2017-08-14 |
4 |
OE |
$10.77 |
$53,850 |
D/D |
5,000 |
33,844 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2017-07-05 |
4 |
D |
$17.95 |
$60,922 |
D/D |
(3,394) |
235,493 |
|
- |
|
Zhou Rong |
EVP, Production Center |
|
2017-06-15 |
4 |
D |
$16.18 |
$2,362 |
D/D |
(146) |
48,096 |
|
- |
|
Gerst Diane G. |
EVP, QA & Regulatory Affairs |
|
2017-06-15 |
4 |
D |
$16.18 |
$2,362 |
D/D |
(146) |
34,348 |
|
- |
|
Prins Richard K |
Director |
|
2017-06-09 |
4 |
S |
$17.07 |
$170,707 |
D/D |
(10,000) |
28,844 |
|
- |
|
Prins Richard K |
Director |
|
2017-06-09 |
4 |
OE |
$10.77 |
$107,700 |
D/D |
10,000 |
38,844 |
|
- |
|
Lee Howard |
Director |
|
2017-06-09 |
4 |
D |
$16.84 |
$30,750 |
D/D |
(1,826) |
118,545 |
|
- |
|
Zasloff Michael A |
Director |
|
2017-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,844 |
38,255 |
|
- |
|
Shohet Stephen B. |
Director |
|
2017-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,844 |
24,116 |
|
- |
|
Prins Richard K |
Director |
|
2017-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,844 |
28,844 |
|
- |
|
Petersen Floyd F. |
Director |
|
2017-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,844 |
64,561 |
|
- |
|
Lee Howard |
Director |
|
2017-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,844 |
120,371 |
|
- |
|
Koo Richard |
Director |
|
2017-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,844 |
235,338 |
|
- |
|
956 Records found
|
|
Page 27 of 39 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|